TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02943629

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apneic oxygenation: Eight minute
Description: A Pentax AWSTM video laryngoscope with attached P blade will be placed and then 10 l/minute flow of oxygen will be administered through the P blade (apneic oxygenation) for eight minutes, or less if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.

Intervention type: DEVICE
Group type: OTHER
Intervention: Without apneic oxygenation
Description: A Pentax AWSTM video laryngoscope with attached P blade will be placed for eight minutes, or less if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.

Intervention type: DEVICE
Group type: OTHER
Intervention: Without apneic oxygenation
Description: A Pentax AWSTM video laryngoscope with attached P blade will be placed for eight minutes, or less if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apneic oxygenation: five minutes
Description: A Pentax AWSTM video laryngoscope with attached P blade will be placed and then 10 l/minute flow of oxygen will be administered through the P blade (apneic oxygenation) for five minutes, or less if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
Study: NCT02620410

Intervention type: DEVICE
Group type: OTHER
Intervention: Axonics Sacral Neuromodulation (SNM) System
Description: The implantable components of the Axonics Sacral Neuromodulation (SNM) System consist of an IPG and tined lead. Additional components include a clinician programmer, surgical tool kit, recharging kit, and patient remote control.
Study: NCT00610376

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preschool handwashing intervention program
Description: This preschool-based intervention program used a multi-pronged approach that included elements aimed at preschool staff, children, and school nurses, as well as hygienic changes to the classroom environment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preschool handwashing intervention program
Description: This preschool-based intervention program used a multi-pronged approach that included elements aimed at preschool staff, children, and school nurses, as well as hygienic changes to the classroom environment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Preschool handwashing intervention program
Description: This preschool-based intervention program used a multi-pronged approach that included elements aimed at preschool staff, children, and school nurses, as well as hygienic changes to the classroom environment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home component intervention
Description: The home component was intended to reinforce handwashing practices through education in the home. It consisted of a video, a magnet, and a card.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home component intervention
Description: The home component was intended to reinforce handwashing practices through education in the home. It consisted of a video, a magnet, and a card.
Study: NCT02346851

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Functional Electrical Stimulation (FES) treatment
Description: This study is randomized controlled trial performed by Random permuted blocks. This study has 2 experimental groups and 1 control group. Both experimental group receive FES treatment of their posterior deltoid and supraspinatus. Experimental group 1(Acceleration group) uses Novastim CU FS1 once a day for 30 minutes during 3 weeks. During treatment patient give a maximal effort for shoulder abduction. Experimental group 2 (Convention group) receive cyclic FES treatment for reducing shoulder subluxation. All patients have evaluation pre-intervention, post-intervention, 3 weeks after intervention and 9 weeks after intervention including physical examination and x-ray.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) treatment
Description: This study is randomized controlled trial performed by Random permuted blocks. This study has 2 experimental groups and 1 control group. Both experimental group receive FES treatment of their posterior deltoid and supraspinatus. Experimental group 1(Acceleration group) uses Novastim CU FS1 once a day for 30 minutes during 3 weeks. During treatment patient give a maximal effort for shoulder abduction. Experimental group 2 (Convention group) receive cyclic FES treatment for reducing shoulder subluxation. All patients have evaluation pre-intervention, post-intervention, 3 weeks after intervention and 9 weeks after intervention including physical examination and x-ray.
Study: NCT00557193

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study: NCT04034745

Intervention type: DRUG
Intervention: telotristat ethyl
Description: 250 mg tablets of Xermelo (telotristat ethyl) is administered orally 3x daily in combination with somatostatin analogs (SSAs) for approximately 84 days as per standard of care
Study: NCT02425111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab intravenous injection
Study: NCT01875744

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol 4000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol 4000
Study: NCT03003845

Intervention type: OTHER
Intervention: Questionnaires
Description: QOL and pain questionnaires will be given to patients at 3, 6, and 12 months post surgery

Intervention type: OTHER
Intervention: Collection of Blood samples
Description: Blood for PBLs will be collected at 3, 6, and 12 months post surgery
Study: NCT04352283

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Preprocedural ultrasound exam of lumbar spine
Description: Preprocedural ultrasound exam of lumbar spine used to determinate needle puncture site
Study: NCT03100227

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PET [18F] FDG
Description: Measurement of carbohydrate metabolism at the individual level. Standardization of the individual imaging data in a standard anatomical space and then calculation of an average image through the group-level controls.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: PET [18F] FDG
Description: Measurement of carbohydrate metabolism at the individual level. Standardization of the individual imaging data in a standard anatomical space and then calculation of an average image through the group-level controls.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anatomical MRI
Description: All subjects will benefit from a 3D anatomical MRI to control the normality of their MRI and an automatic segmentation of 73 brain regions by multi-atlas segmentation.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Anatomical MRI
Description: All subjects will benefit from a 3D anatomical MRI to control the normality of their MRI and an automatic segmentation of 73 brain regions by multi-atlas segmentation.
Study: NCT04554082

Intervention type: PROCEDURE
Intervention: laparoscopic sleeve gastrectomy
Description: bariatric surgery to loss weight

Intervention type: PROCEDURE
Intervention: laparoscopic sleeve gastrectomy
Description: bariatric surgery to loss weight
Study: NCT00477035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIK cells
Description: 2x10e8 cells/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 60 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bcnu
Description: 15 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 100 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1250 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Description: 30 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: 200 mg/m2
Study: NCT01613274

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gum chewing
Description: gum chewing three times a day for up to 20 minutes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no gum chewing
Description: no gum chewing
Study: NCT03264846

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of Serum and Saliva Samples
Description: Whole saliva samples were obtained via expectorating into polypropylene tubes venous blood were obtained from the antecubital vein via the standard venipuncture method.

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of Serum and Saliva Samples
Description: Whole saliva samples were obtained via expectorating into polypropylene tubes venous blood were obtained from the antecubital vein via the standard venipuncture method.

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of Serum and Saliva Samples
Description: Whole saliva samples were obtained via expectorating into polypropylene tubes venous blood were obtained from the antecubital vein via the standard venipuncture method.

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of Serum and Saliva Samples
Description: Whole saliva samples were obtained via expectorating into polypropylene tubes venous blood were obtained from the antecubital vein via the standard venipuncture method.
Study: NCT03414658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: work by interfering with cell division, which leaves the tumor unable to grow and spread

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: work by interfering with cell division, which leaves the tumor unable to grow and spread

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: work by interfering with cell division, which leaves the tumor unable to grow and spread

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utomilumab
Description: Utomilumab is an antibody designed to stimulate the body's immune system to fight cancer cells
Study: NCT04135989

Intervention type: DEVICE
Group type: OTHER
Intervention: Percutaneous coronary intervention with implantation of amphilimus-eluting stents for coronary artery disease.
Description: Implantation of polymer-free, amphilimus-eluting, drug-eluting stents

Intervention type: DEVICE
Group type: OTHER
Intervention: Percutaneous coronary intervention with implantation of amphilimus-eluting stents for coronary artery disease.
Description: Implantation of polymer-free, amphilimus-eluting, drug-eluting stents

Intervention type: DEVICE
Group type: OTHER
Intervention: Percutaneous coronary intervention with implantation of everolimus-eluting stents for coronary artery disease.
Description: Implantation of biodegradable-polymer, everolimus-eluting, drug-eluting stents

Intervention type: DEVICE
Group type: OTHER
Intervention: Percutaneous coronary intervention with implantation of everolimus-eluting stents for coronary artery disease.
Description: Implantation of biodegradable-polymer, everolimus-eluting, drug-eluting stents

Intervention type: DRUG
Group type: OTHER
Intervention: Personalized DAPT duration
Description: Duration of dual antiplatelet therapy according to DAPT score for 3- or 6- months in patients with low DAPT score (stable CAD or ACS, respectively) or for 24-months in patients with high DAPT score

Intervention type: DRUG
Group type: OTHER
Intervention: Personalized DAPT duration
Description: Duration of dual antiplatelet therapy according to DAPT score for 3- or 6- months in patients with low DAPT score (stable CAD or ACS, respectively) or for 24-months in patients with high DAPT score

Intervention type: DRUG
Group type: OTHER
Intervention: Standard DAPT duration
Description: Duration of dual antiplatelet therapy for 12 months.

Intervention type: DRUG
Group type: OTHER
Intervention: Standard DAPT duration
Description: Duration of dual antiplatelet therapy for 12 months.
Study: NCT01288326

Intervention type: DRUG
Intervention: liraglutide
Description: Liraglutide will be prescribed and titrated (individually adjusted) by the treating physician.
Study: NCT01120418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Besifloxacin Ophthalmic Suspension 0.6%
Description: administered 3 times a day for 5 days to one eye.
Study: NCT04577612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHI-554
Description: hemp-derived CBD in MCT oil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHI-554
Description: hemp-derived CBD in MCT oil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHI-554
Description: hemp-derived CBD in MCT oil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CHI-554
Description: hemp-derived CBD in MCT oil
Study: NCT03293056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval Hydrogynmastics
Description: The HIIH to PSE group during the high intensity (HI) period should remain between 16 to 18 points, while in the moderate intensity (MI) intervals around 11. The dynamic exercises will progression, in the first month will be 1 min of HI and 2 min of MI, in the second month of 1 min of HI and 1 min of MI and in the last month of 1 min of HI and 30 s of MI, until completing 30 min in total.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydrogynmastics Continuous Moderate
Description: For the HCM group the PSE will be around 11 points during the 30 min of moderate continuous exercise. In both groups the form of intensity monitoring that will be through the PSE, in which this scale will be printed in banner form and affixed next to the physical education teacher during the classes.
Study: NCT02561039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate
Description: Participants will receive ibandronate, either as a 6-mg IV infusion every 3 to 4 weeks or a 50-mg tablet PO daily, for 4 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate
Description: Participants will receive ibandronate, either as a 6-mg IV infusion every 3 to 4 weeks or a 50-mg tablet PO daily, for 4 months.
Study: NCT03840486

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-rebreather mask (NRBM)
Description: The non-rebreather mask (NRBM) will be used to assist in the delivery of oxygen. Participants will be placed on NRBM at different flow rates (15 LPM, 35 LPM, or Flush rate at 55 LPM).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive ventilator mask (NIV)
Description: The NIV is a non-invasive face (nasal) mask for oxygen delivery. Participants will receive oxygen at 50% FiO2 for 3 minutes, 75% FiO2 for 3 minutes or 100% FiO2 for 3 minutes each.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal cannula EtO2 sensor
Description: The nasal cannula EtO2 sensor will be placed on the participant's face under the mask to detect the EtO2 levels.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal cannula EtO2 sensor
Description: The nasal cannula EtO2 sensor will be placed on the participant's face under the mask to detect the EtO2 levels.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen (NRBM)
Description: Oxygen will be delivered via the NRBM. Participants will receive oxygen at different flow rates (15 LPM, 35 LPM, or flush rate at 55 LPM).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen (NIV)
Description: Oxygen will be delivered via the NIV mask. Participants will receive oxygen at 50% FiO2, 75% FiO2 or 100% FiO2 for 3 minutes each.
Study: NCT03519737

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tPA in combination with the Sonolysis Headframe (TUS)
Description: tPA: 60 minutes per approved labeling TUS insonation via the Sonolysis Headframe: minimum 90 minutes - maximum 120 minutes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tPA in combination with the Sonolysis Headframe (Sham TUS)
Description: tPA per approved labeling Sham (inactive) TUS insonation via the Sonolysis Headframe: minimum 90 minutes - maximum 120 minutes
Study: NCT02988817

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enapotamab vedotin (HuMax-AXL-ADC)
Description: Enapotamab vedotin (HuMax-AXL-ADC) will be administered intravenously.
Study: NCT03082846

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiation
Description: The simultaneous integrated boost-intensity modulated technology is adopted to increase both the dose in the surgical cavity and residual tumor (PTV1).The dose at each fraction is gradually increased from 2.8 Gy/f (total of 20 times) with an escalating dose interval of 0.4 Gy in PTV1, until dose-limiting toxicity is present,the highest target single dose is 4 Gy/f. The planning target volume (PTV2) including the 2 cm region around surgical cavity and residual tumor remain unchanged, with 2.5 Gy each time and a total of 50 Gy/20f.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide chemotherapy
Description: Temozolomide(TMZ) is administered orally every day at 75 mg/m2 during radiotherapy and at 150-200 mg/m2 for 12 cycles following completion of chemoradiotherapy.
Study: NCT02455752

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LE-TME
Description: Retroperitoneal approach for total mesorectal excision
Study: NCT02277288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Filled bladder arm
Description: Bladder to be instilled with 200 cc fluid during cystoscopy and no catheter for all mid-urethral sling procedures.
Study: NCT00831675

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine 2004-2005 Paediatric Formulation
Description: 0.25 mL (Day 0 and Day 28), Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine 2004-2005 Paediatric Formulation
Description: 0.25 mL (Day 0 and Day 28), Intramuscular
Study: NCT02244060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Priming effect from vignette
Description: In the arm of DCV, the self-assessed vision (PSAV) is listed after the vignette questions; however, in the arm of ICV, the self-assessment of vision (SAV) is listed before the vignette questions. Priming effect from vignette will be estimated by comparing those two randomized variables (i.e., SAV and PSAV).
Study: NCT02122445

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cramer Sports Motion Tape
Description: lower body exercises with and without Cramer Sports Motion tape applied to the hip
Study: NCT02867670

Intervention type: DEVICE
Intervention: Transcranial Magnetic Stimulation
Description: TMS is a form of non-invasive brain stimulation which uses magnetic pulses to stimulate regions of the brain from outside the head, on the scalp. Specifically, TMS is performed with a copper-and-plastic coil that emits a magnetic field, which can affect brain cells in specific locations. In this study, researchers will also use a form of TMS called theta-burst stimulation (TBS), where TMS pulses are delivered rapidly over time.

Intervention type: DEVICE
Intervention: Transcranial Magnetic Stimulation
Description: TMS is a form of non-invasive brain stimulation which uses magnetic pulses to stimulate regions of the brain from outside the head, on the scalp. Specifically, TMS is performed with a copper-and-plastic coil that emits a magnetic field, which can affect brain cells in specific locations. In this study, researchers will also use a form of TMS called theta-burst stimulation (TBS), where TMS pulses are delivered rapidly over time.
Study: NCT03626558

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasound measures
Description: It is three diaphragmatic ultrasounds measures of a duration of twenty minutes each approximately. The diaphragmatic ultrasound is practised by trans-thoracic way and is non-invasive, completely painless and does not require the exposure of patients to radiation.
Study: NCT04957069

Intervention type: PROCEDURE
Intervention: fixation
Description: double row fixation with 3-4 wire anchors

Intervention type: PROCEDURE
Intervention: primary repair
Description: end-to-end repair
Study: NCT05973812

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Infant formula supplemented with Bifidobacterium breve PS1
Description: Feeding with an infant formula containing 7 log10 cfu of the strain per gram of formula.

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Infant formula NOT supplemented with Bifidobacterium breve PS1
Description: Feeding with the same infant formula but without supplementation with the B. breve strain
Study: NCT02167906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: arterial stiffness measurement

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: arterial stiffness measurement
Study: NCT02367924

Intervention type: DRUG
Intervention: trabectedin
Description: The administration of chemotherapy regimen with trabectedin (according to Summary of Product Characteristics (SmPC)) will be determined by the Investigator's discretion depending on the patients' conditions and previous chemotherapy.
Study: NCT00710515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: 75mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: 75mg
Study: NCT02282085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole Once-Monthly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc)
Description: Oral antipsychotic medication
Study: NCT01816958

Intervention type: OTHER
Intervention: co-administration of TMS and infused ketamine
Description: co-administration of TMS and infused ketamine